COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab - Cross, Anne H. (Department of Neurology. Washington University) ; Delgado, Silvia (University of Miami Miller School of Medicine) ; Habek, Mario (University Hospital Center Zagreb. University of Zagreb. School of Medicine) ; Davydovskaya, Maria (Moscow State Public Healthcare InsCity Clinical Hospital 24) ; Ward, Brian J. (Infectious Diseases Division. Research Institute of the McGill University Health Centre) ; Cree, Bruce A. C (UCSF Weill Institute for Neurosciences. Department of Neurology. University of California San Francisco) ; Totolyan, Natalia (First Saint Petersburg State Medical University) ; Pingili, Ratnakar (Novartis Pharmaceuticals Corporation) ; Mancione, Linda (Novartis Pharmaceuticals Corporation) ; Hu, Xixi (Novartis Pharmaceuticals Corporation) ; Sullivan, Roseanne (Novartis Pharmaceuticals Corporation) ; Su, Wendy (Novartis Pharmaceuticals Corporation) ; Zielman, Ronald (Novartis Pharma B.V.) ; Gupta, Ayan Das (Novartis Healthcare Private Limited) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Winthrop, Kevin (School of Public Health at Oregon Health and Science University) ; Universitat Autònoma de Barcelona. Departament de Medicina
 
Comentarios (0) | Reseñas (0)
Sea el primero a escribir una reseña de este documento.

Añada su reseña

Valore este artículo:
Dé un título a su reseña:
Escriba su reseña:
Atención: todavía no ha definido su alias.
N/D, será el que se muestre como autor de este comentario